

Appendix 1:

Guidance for immunocompromised individuals

Moderately to severely immunocompromised:

Individuals with expectation for 1-year survival prior to SARS-CoV-2 infection and with at least one of the following:

- Receipt for solid tumors and hematologic malignancies (including individuals with lymphoid malignancies who are being monitored without active treatment)
- Receipt of solid-organ transplant AND taking immunosuppressant therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome, common variable immunodeficiency, Good's syndrome, hyper IgE syndrome)
- Advanced or untreated HIV infection
- Active treatment with high dose corticosteroids (i.e. ≥ 20 mg prednisone or equivalent per day for at least ≥ 2 weeks)
- Receiving alkylating agents, antimetabolites, transplant-related immunosuppressant drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory